Participated · Series A · Mar 2026

AvoMD builds a clinical AI platform designed to synthesize patient data, surface evidence-based guidance, and support clinicians with end-to-end AI copilots embedded in the EHR. The company positions its product to reduce clinician friction caused by fragmented datasets and multiple applications, aiming to drive measurable improvements in outcomes, cost savings, revenue, and operational efficiency. AvoMD announced a strategic partnership with DynaMed from EBSCO Clinical Decisions to integrate trusted evidence-based knowledge into the EHR via Ask Avo. The business emphasized clinician-centric design, saying it delivers results “with love, not alerts.” Financially, AvoMD has secured a $10M Series A to accelerate product development and commercialization. The announcement credits engaged customers, partners, and its team for supporting the company's growth.

Participated · Series A · Oct 2025

Confido Health is a US-based healthcare technology company building AI voice agents that fully replace traditional phone trees for medical practices. The platform answers on the first ring, authenticates callers, verifies eligibility, and completes tasks such as referrals, prescription refills, payments, status checks, and appointment bookings, with every interaction logged directly in the electronic health record. When a case is too complex, the system seamlessly transfers the call to human staff, aiming to reduce stress on front-desk teams while improving patient access. Confido positions its product for multi-site operators by centralizing patient access on a single platform to create a cohesive experience, cut overhead costs, and support growth. The company cites market data showing that more than 80% of patients use phones to reach providers and that fewer than half of calls are resolved on the first attempt, highlighting the need for its solution. Proceeds from the latest funding will be used to enhance the AI voice agent platform and scale its deployment. Including the new Series A round, Confido Health has raised a total of $13 million to date.

Participated · Equity · Jun 2023

Gradient Health operates a secure, unified platform that gives researchers and developers access to raw and labeled medical images needed to train and validate AI technologies. The company offers machine-learning-ready formatting, searchable access by disease and imaging modality, and tools to facilitate compliant research and seamless collaborations. It emphasizes state-of-the-art security measures to protect patient privacy and ensure regulatory compliance. Gradient Health collaborates with academic institutions, healthcare organizations, and technology partners to advance medical knowledge and improve patient care. Led by CEO Josh Miller, the company recently raised $2.75M and intends to use the proceeds to continue assembling its comprehensive annotated medical imaging library.

Participated · Seed · Jun 2023

eddii is a diabetes-management app that integrates with Dexcom's real-time APIs to gamify continuous glucose monitor (CGM) data through a virtual in-app character. The app delivers games, educational character-led activities, AI-enabled conversation, real-time feedback, and in-app rewards to engage children living with type 1 diabetes. eddii's integration supports Dexcom G6 and G7 and streams real-time glucose updates into its interface. In a randomized controlled trial enrolling 92 children using Dexcom CGM, eddii produced a statistically significant 5% improvement in Time In Range, roughly 1.5 additional hours per day. The company will launch a beta in Oklahoma in the summer and plans a nationwide U.S. rollout later in the year, with intentions to expand into adult T1D and adjacent markets. eddii recently closed a $2.5M seed round led by Kapor Capital with participation from Atento Capital, MedMountain Ventures (MMV), StartUp Health, and angel investors; the CEO and founder is Farhaneh Ahmadi, PhD, who lives with T1D.

Participated · Seed · Nov 2022

Options MD operates a virtual-care platform focused on treatment-resistant depression, where patients complete a screening form and can have intake sessions with psychiatrists. The company offers a range of treatments including talk therapy, new medications, transcranial magnetic stimulation (TMS) and ketamine. Options MD says it is nurturing one of the country's largest communities for treatment-resistant depression and emphasizes comprehensive, personalized care. The startup plans to use new funding to expand clinical operations and research and to improve its proprietary clinical protocols. Financially, Options MD has raised pre-seed capital totaling nearly $4 million following its latest round and additional support from a Google for Startups Latino Founders Fund award.